SBIR-STTR Award

Ion Channel Drug Discovery Using Photoswitch Technology
Award last edited on: 3/21/13

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$1,534,910
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Andrew L Blatz

Company Information

Photoswitch Biosciences Inc

1600 Adams Drive Suite 105
Menlo Park, CA 94025
   (650) 773-2942
   info@photoswitchbio.com
   www.photoswitchbio.com
Location: Single
Congr. District: 18
County: San Mateo

Phase I

Contract Number: 1R43GM087755-01A2
Start Date: 1/4/10    Completed: 12/31/10
Phase I year
2010
Phase I Amount
$334,910
Ion channels are membrane proteins that allow the selective movement of charged molecules through cellular membranes. Many disease states, such as cystic fibrosis, muscular dystrophies, hypertension, and cardiac arrhythmias are caused by ion channel pathologies. Ion channels have been identified by the drug discovery community as excellent targets for therapeutic intervention but because of the technical hurdles involved in developing quality, high-throughput functional ion channel assays, the development of [QOUTA]ion channel drugs[QOUTA] has been disappointing. Photoswitch Biosciences has developed technology, which allows attaching small nanomachines to ion channels enabling rapid and reversible control of these proteins by light. The three Specific Aims of the proposed project are: (1) optimization of the dynamic range of changes in membrane potential driven by photoswitched channels in mammalian cell lines, (2) optimization of cell line, photoswitched channel and membrane potential range to assay several voltage-gated ion channel targets using electrophysiological detection, and (3) conversion of the assay to an all-optical readout by substituting indicator dyes for electrophysiology detection. The first commercial products to be developed will be all-optical ion channel assays and instruments for high- throughput ion channel drug discovery. The use of all-optical technology for ion channel assays has several advantages over existing techniques: (1) Elimination of liquid additions for channel activation, (2) Highly scalable for high-throughput ion channel drug discovery, (3) Price per datapoint is at least 100X less than automated electrophysiology, (4) Channel activation is almost 100X faster than KCl addition. The most important benefit of this new ion channel assay technology is the ability to rapidly and reliably control membrane potential. This control of membrane potential allows for the development of scalable high-throughput state-dependent assays, which is impossible with current technology. This breakthrough technology will finally allow the full exploitation of ion channels as drug targets.

Public Health Relevance:
Many diseases involve problems with the functioning of membrane proteins called ion channels. These proteins are responsible for proper operation of the nervous system, the muscles, and virtually all other physiological events. Drugs that affect ion channel behavior have been developed for a variety of diseases, including heart problems, cystic fibrosis, and other diseases. Ion channels are difficult to study and, because of this, drugs directed at ion channels have been difficult to find. Photoswitch Biosciences proposes to develop methods to increase the ability to study ion channels, and, thus, to increase the number of ion channel drugs.

Thesaurus Terms:
Address; Adoption; Affect; Arrhythmia; Arts; Assay; Behavior; Bioassay; Biologic Assays; Biological Assay; Blood Pressure, High; Brain; Cardiac Arrhythmia; Cell Line; Cell Lines, Strains; Cellline; Cells; Cellular Membrane; Charge; Coloring Agents; Communities; Cultured Cells; Cystic Fibrosis; Data; Detection; Development; Device Or Instrument Development; Disease; Disorder; Drug Delivery; Drug Delivery Systems; Drug Targeting; Drug Targetings; Drugs; Dyes; Electrophysiology; Electrophysiology (Science); Encephalon; Encephalons; Event; Gated Ion Channel; Glutamate Receptor; Goals; Heart; Heart Arrhythmias; Hypertension; Illumination; Ion Channel; Ion Channels, Potassium; Ionic Channels; Ions; K Channel; Light; Lighting; Liquid Substance; Mammalian Cell; Medication; Membrane Channels; Membrane Potentials; Membrane Proteins; Membrane-Associated Proteins; Methods; Methods And Techniques; Methods, Other; Movement; Mucoviscidosis; Muscle; Muscle Tissue; Muscular Dystrophies; Myodystrophica; Myodystrophy; Nrvs-Sys; Nerve Cells; Nerve Unit; Nervous System; Nervous System, Brain; Nervous System Structure; Neural Cell; Neurocyte; Neurologic Body System; Neurologic Organ System; Neurons; Neurophysiology / Electrophysiology; Operation; Operative Procedures; Operative Surgical Procedures; Optical Methods; Optics; Outcome; Pathology; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Photoradiation; Physiologic; Physiological; Potassium Channel; Price; Property; Property, Loinc Axis 2; Proteins; Research Resources; Resources; Rest; Resting Potentials; Screening Procedure; Slice; Solutions; Stretching; Surface Proteins; Surgical; Surgical Interventions; Surgical Procedure; System; System, Loinc Axis 4; Techniques; Technology; Testing; Therapeutic Intervention; Time; Transmembrane Potentials; V (Voltage); Vascular Hypertensive Disease; Vascular Hypertensive Disorder; Voltage-Clamp Technics; Voltage-Clamp Technique; Work; Assay Development; Base; Body Movement; Cell Type; Cultured Cell Line; Device Development; Disease/Disorder; Drug Discovery; Drug/Agent; Experiment; Experimental Research; Experimental Study; Fluid; Gene Product; Hyperpiesia; Hyperpiesis; Hypertensive Disease; Instrument; Instrument Development; Interest; Intervention Therapy; Light Gated; Liquid; Nano Machine; Nanomachine; Neuronal; Novel; Patch Clamp; Pricing; Public Health Relevance; Research Study; Response; Screening; Screenings; Stable Cell Line; Success; Surgery; Voltage

Phase II

Contract Number: 2R44GM087755-02A1
Start Date: 1/4/10    Completed: 1/31/14
Phase II year
2012
(last award dollars: 2013)
Phase II Amount
$1,200,000

Ion channels are membrane proteins that allow the selective movement of charged molecules through cellular membranes. Many disease states, such as cystic fibrosis, muscular dystrophies, hypertension, and cardiac arrhythmias are caused by ion channel pathologies. Ion channels have been identified by the drug discovery industry as excellent targets for therapeutic intervention but because of the technical hurdles involved in developing quality, high- throughput functional ion channel assays, the development of "ion channel drugs" has been disappointing. Photoswitch Biosciences has developed technology, which allows attaching small nanomachines to ion channels enabling rapid and reversible control of these proteins by light. The Specific Aims of this proposed Phase II SBIR project are: (1) generation of several stable cell lines expressing photoswitched ion channels, accessory channels, and test channels; (2) produce three functional prototype instruments for sale to early access collaborators. As part of Specific Aim 2 we will evaluate illumination and detection strategies and implement the most appropriate. The first commercial products to be developed will be all-optical ion channel assays and instruments for high- throughput ion channel drug discovery. The use of all-optical technology for ion channel assays has several advantages over existing techniques: (1) Elimination of liquid additions for channel activation, (2) Highly scalabl for high-throughput ion channel drug discovery, (3) Price per datapoint is at least 100X less than automated electrophysiology, (4) Channel activation is almost 100X faster than KCl addition. The most important benefit of this new ion channel assay technology is the ability to rapidly and reliably control membrane potential. This control of membrane potential allows for the development of scalable high-throughput state-dependent assays, which is impossible with current technology. This breakthrough technology will finally allow the full exploitation of ion channels as drug targets.

Public Health Relevance:
Many diseases involve problems with the functioning of membrane proteins called ion channels. These proteins are responsible for proper operation of the nervous system, the muscles, and virtually all other physiological events. Drugs that affect ion channel behavior have been developed for a variety of diseases, including heart problems, cystic fibrosis, and other diseases. Ion channels are difficult to study and, because of this, drugs directed at ion channels have been difficult to find. Photoswitch Biosciences proposes to develop methods to increase the ability to study ion channels, and, thus, to increase the number of ion channel drugs.

Public Health Relevance Statement:
Many diseases involve problems with the functioning of membrane proteins called ion channels. These proteins are responsible for proper operation of the nervous system, the muscles, and virtually all other physiological events. Drugs that affect ion channel behavior have been developed for a variety of diseases, including heart problems, cystic fibrosis, and other diseases. Ion channels are difficult to study and, because of this, drugs directed at ion channels have been difficult to find. Photoswitch Biosciences proposes to develop methods to increase the ability to study ion channels, and, thus, to increase the number of ion channel drugs.

Project Terms:
Affect; Area; Arrhythmia; assay development; base; Beds; Behavior; Biological Assay; Cell Culture Techniques; Cell Line; Cells; Cellular Membrane; Charge; charge coupled device camera; commercialization; Complement; Computer software; Cystic Fibrosis; design; Detection; detector; Development; Devices; Disadvantaged; Disease; Drug Delivery Systems; drug discovery; Dyes; Economics; Electrophysiology (science); Ensure; Event; Exhibits; Fluorescence; Generations; Goals; Heart; Hypertension; Industry; insight; instrument; instrumentation; inward rectifier potassium channel; Ion Channel; Light; light intensity; Lighting; Liquid substance; Market Research; Measures; meetings; Membrane Potentials; Membrane Proteins; Methods; Movement; Muscle; Muscular Dystrophies; nanomachine; Nervous system structure; novel; operation; Optics; Pathology; Pharmaceutical Preparations; Pharmacologic Substance; Phase; phase 1 study; photomultiplier; Physiological; Price; Proteins; Protocols documentation; prototype; quantum; Reader; Reagent; Reporting; Research; response; Rest; Sales; Screening procedure; Small Business Innovation Research Grant; software development; stable cell line; success; System; Techniques; Technology; Testing; Therapeutic Intervention; Tube; voltage; voltage-dependent calcium channel (P-Q type)